Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris J Edgar

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 29, 2023
Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task ForceChris J Edgar, Elizabeth Nicki Bush, Heather R Adams, et al.
Schizophrenia Research|January 13, 2015
Defining therapeutic benefit for people with schizophrenia: focus on negative symptomsNina R Schooler, Robert W Buchanan, Thomas Laughren, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 1, 2021
Building clinically relevant outcomes across the Alzheimer's disease spectrumDorene M Rentz, Alette M Wessels, Ananth V Annapragada, et al.
Brain : a Journal of Neurology|November 6, 2024
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutationJan Smeitink, Just van Es, Brigitte Bosman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 10, 2022
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trialsJessica B Langbaum, Julie Zissimopoulos, Rhoda Au, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 29, 2023
Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task ForceChris J Edgar, Elizabeth Nicki Bush, Heather R Adams, et al.
Schizophrenia Research|January 13, 2015
Defining therapeutic benefit for people with schizophrenia: focus on negative symptomsNina R Schooler, Robert W Buchanan, Thomas Laughren, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 1, 2021
Building clinically relevant outcomes across the Alzheimer's disease spectrumDorene M Rentz, Alette M Wessels, Ananth V Annapragada, et al.
Brain : a Journal of Neurology|November 6, 2024
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutationJan Smeitink, Just van Es, Brigitte Bosman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 10, 2022
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trialsJessica B Langbaum, Julie Zissimopoulos, Rhoda Au, et al.
Pageof 2